ClinicalTrials.gg
CompletedNCT01451827NOCTURNEUpdated Sep 27, 2018Results posted

8-Week Study of Tolvaptan Dose Forms in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

A Phase 2 interventional study of Tolvaptan MR and Tolvaptan IR in Autosomal Dominant Polycystic Kidney Disease, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2018-09-27.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
178
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant — none open to participants now, none under way, none of them phase 3. Tolvaptan · Polycystic Kidney, Autosomal Dominant.

Enrollment
5th of 18
178 · median 91
Started
2011
the only one that year
Phase 2
7 of 18
none open now
Registered
9th of 18
by date
Lead sponsor
9 of 18
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant, this one is the 5th largest by enrollment, is the only one that started in 2011, is one of 7 in phase 2, and was the 9th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

None of the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant is open now. The open studies under Polycystic Kidney, Autosomal Dominant, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 18 studies testing tolvaptan in Polycystic Kidney, Autosomal Dominant as a file.
02

Study summary

The purpose of this study is to compare the short-term effects of two tolvaptan formulations in patients with ADPKD.

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease

Keywords

  • Kidney Disease
  • Polycystic Kidney Disease
  • Autosomal Dominant Polycystic Kidney Disease
  • PKD
  • ADPKD
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 50
  2. Subjects with:

    • between 19 and 35 kg/m2
    • diagnosis of ADPKD by modified Ravine criteria:

      • family history: 3cysts/kidney if by sonography or 5 by CT or MRI
      • Without family history: 10 cysts per kidney
    • an > 45 mL/min/1.73 m2 by the CKD-EPI equation
  3. Subjects not planning to become pregnant willing to comply with requirements.
  4. Subjects must be in good health as determined by screening tests.
  5. Subjects providing and able to comply with all trial requirements.

Exclusion criteria

Exclusion Criteria:

  1. Subjects using diuretics within 14 days prior to randomization, or the requirement for intermittent or constant diuretic use for any reason
  2. Subjects who had an \< 45 mL/min/1.73 m2 calculated based on the most recent historical creatinine during the last 12 months
  3. Subjects with:

    • incontinence, overactive bladder, or urinary retention (eg, BPH), meaning subjects with symptoms of frequent nocturia, as determined by medical history or urinary urgency should be carefully evaluated to exclude non-ADPKD GU issues prior to entry.
    • liver disease, liver function abnormalities, or serology other than that expected for ADPKD with cystic liver disease at baseline
    • a history of renal surgery or cyst drainage within 6 months of randomization
    • blood pressure 150/95 mmHg or \< 90/40 mmHg.
    • heart rate outside the range of 40 to 90 bpm.
    • advanced diabetes with a history of poor control, evidence of significant renal disease renal cancer, single kidney, or recent renal surgery
    • other significant medical history that may interfere with the study objectives
    • significant abnormalities in serum sodium concentration (\< 135 or > 145 mEq/L)
    • a history of drug and/or alcohol abuse within 2 years prior to screening
    • allergic reactions to tolvaptan or chemically related structures such as benzazepines (eg, benzazepril, conivaptan, fenoldopam mesylate, or mirtazapine)
  4. Subjects having taken an drug within 30 days preceding randomization on Day 0
  5. Subjects taking medications or having concomitant illnesses likely to confound endpoint assessments, including taking approved (ie, marketed) therapies for the purpose of affecting PKD cysts such as tolvaptan, somatostatin agonists (ie, octreotide, sandostatin), Rapamune (sirolimus), anti-sense RNA therapies, other vasopressin antagonists (eg, OPC-31260 [mozavaptan] and Vaprisol® [conivaptan]) or agonists (eg, desmopressin), and cyst reduction surgery
  6. Subjects on antihypertensives that have not been on the same antihypertensive regimen for at least 30 days prior to the first dose of IMP
  7. Subjects having to, or interference with, MRI assessments
  8. Subjects with a history of serious mental disorders that, in the opinion of the investigator, would exclude the subject from participating in this trial
  9. Subjects with previous exposure to tolvaptan
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
178 participants (actual)

Study arms

  • Experimental
    Tolvaptan MR 50 mg

    Tolvaptan MR 50 mg capsule and 2 placebo IR tablets ( 8 AM) and 1 placebo IR tablet (4 PM) daily.

    Drug: Tolvaptan MR · Drug: Placebo

  • Experimental
    Tolvaptan MR 80 mg

    Tolvaptan MR 80 mg capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.

    Drug: Tolvaptan MR · Drug: Placebo

  • Experimental
    Tolvaptan IR 60/30 mg

    Two tolvaptan IR 30-mg tablets and 1 placebo MR capsule (8 AM) and 1 tolvaptan IR 30-mg tablet (4 PM) daily.

    Drug: Tolvaptan IR · Drug: Placebo

  • Placebo comparator
    Placebo

    Placebo MR capsule and 2 placebo IR tablets (8 AM) and 1 placebo IR tablet (4 PM) daily.

    Drug: Placebo

Interventions

  • 50/80 mg capsules

    Also known as: OPC-41061

  • 60/30 mg capsules

    Also known as: OPC-41061

  • DrugPlacebo

    tablet

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3

    The primary endpoint was percent change from baseline in TKV at Week 3. Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.

    Time frame: Baseline to Week 3

Secondary outcomes

  1. Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS)

    The ADPKD-UIS was a self-administered questionnaire designed to measure ADPKD-related urinary symptoms in participants with ADPKD. This instrument contained 11 items in 3 domains (Urinary Frequency, Urinary Urgency, and Nocturia). Each item was scored using a scale of 1 to 5 (a higher score indicated increased difficulty/extremely bothered). The maximum total score is 55; 1: not difficult/not bothered at all; 55: extremely difficult/extremely bothered.

    Time frame: Baseline to Week 8

  2. Percent Change From Baseline in TKV at Week 8.

    Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.

    Time frame: Baseline to Week 8

07

Results

Posted Aug 13, 2018

Participant flow

The trial was conducted in 177 participants at 41 trial states in the United States.

Participant flow — Overall Study
MilestoneTolvaptan Modifed Release (MR) 50 mgTolvaptan MR 80 mgTolvaptan Immediate Release (IR) 60/30 mgPlacebo
Started45454443
Completed42404239
Not completed3524
Withdrew: Adverse event2011
Withdrew: Protocol deviation1000
Withdrew: Lost to follow-up0302
Withdrew: Participant met withdrawal criteria0200
Withdrew: Withdrawal by subject0011

Outcome measures

PrimaryPercent Change From Baseline in Total Kidney Volume (TKV) at Week 3

The primary endpoint was percent change from baseline in TKV at Week 3. Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.

Time frame:
Baseline to Week 3
Reported as:
Mean · Percentage change
Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3
Percentage changeTolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlacebo
Percent Change From Baseline in Total Kidney Volume (TKV) at Week 3-2.46 ± 4.40-2.55 ± 3.85-1.17 ± 4.520.09 ± 5.31
Statistical analysis
  • Tolvaptan MR 50 mg vs Tolvaptan MR 80 mg vs Tolvaptan IR 60/30 mg vs Placebo · ANCOVA · p = 0.0127 · Ratio of geometric means: 0.98 · 95% CI 0.96 to 1.00
  • Tolvaptan MR 80 mg vs Placebo · ANCOVA · p = 0.0108 · Ratio of geometric means: 0.97 · 95% CI 0.95 to 0.99
  • Tolvaptan MR 50 mg vs Placebo · ANCOVA · p = 0.0155 · Ratio of geometric means: 0.98 · 95% CI 0.96 to 1.00
  • Tolvaptan IR 60/30 mg vs Placebo · ANCOVA · p = 0.2417 · Ratio of geometric means: 0.99 · 95% CI 0.97 to 1.01
SecondaryChange From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS)

The ADPKD-UIS was a self-administered questionnaire designed to measure ADPKD-related urinary symptoms in participants with ADPKD. This instrument contained 11 items in 3 domains (Urinary Frequency, Urinary Urgency, and Nocturia). Each item was scored using a scale of 1 to 5 (a higher score indicated increased difficulty/extremely bothered). The maximum total score is 55; 1: not difficult/not bothered at all; 55: extremely difficult/extremely bothered.

Time frame:
Baseline to Week 8
Reported as:
Mean · Unit on a scale
Change From Baseline in Total Score of the Autosomal Dominant Polycystic Kidney Disease Urinary Impact Scale (ADPKD-UIS)
Unit on a scaleTolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlacebo
Urinary Frequency0.74 ± 0.940.82 ± 0.830.99 ± 0.780.10 ± 0.35
Urinary Urgency0.69 ± 0.960.66 ± 0.771.01 ± 0.950.05 ± 0.30
Nocturia0.97 ± 1.281.15 ± 0.891.36 ± 1.120.11 ± 0.59
Statistical analysis
  • Tolvaptan MR 50 mg vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): 0.65 · 95% CI 0.31 to 0.99
  • Tolvaptan MR 80 mg vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 0.74 · 95% CI 0.40 to 1.08
  • Tolvaptan IR 60/30 mg · ANCOVA · p = < 0.0001 · Mean difference (final values): 0.92 · 95% CI 0.58 to 1.25
  • Tolvaptan MR 50 mg vs Placebo · ANCOVA · p = 0.0004 · Mean difference (final values): 0.66 · 95% CI 0.30 to 1.01
  • Tolvaptan MR 80 mg vs Placebo · ANCOVA · p = 0.0004 · Mean difference (final values): 0.65 · 95% CI 0.29 to 1.01
  • Tolvaptan IR 60/30 mg vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 0.99 · 95% CI 0.63 to 1.34
  • Tolvaptan MR 50 mg vs Placebo · ANCOVA · p = 0.0002 · Mean difference (final values): 0.86 · 95% CI 0.42 to 1.30
  • Tolvaptan MR 80 mg vs Placebo · ANCOVA · p = < 0.0001 · Median difference (final values): 1.07 · 95% CI 0.63 to 1.51
  • Tolvaptan IR 60/30 mg vs Placebo · ANCOVA · p = < 0.0001 · Mean difference (final values): 1.23 · 95% CI 0.80 to 1.66
SecondaryPercent Change From Baseline in TKV at Week 8.

Total kidney volume is an important measure of disease progression. A 3-week time point is adequate to assess acute effects on kidney cyst shrinkage.

Time frame:
Baseline to Week 8
Reported as:
Mean · Percentage change
Percent Change From Baseline in TKV at Week 8.
Percentage changeTolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlacebo
Percent Change From Baseline in TKV at Week 8.-2.04 ± 3.87-2.02 ± 3.54-0.08 ± 7.312.13 ± 7.99
Statistical analysis
  • Tolvaptan MR 50 mg vs Tolvaptan MR 80 mg vs Tolvaptan IR 60/30 mg vs Placebo · ANCOVA · p = 0.0209 · Ratio of geometric means: 0.97 · 95% CI 0.94 to 0.99
  • Tolvaptan MR 80 mg vs Placebo · ANCOVA · p = 0.0287 · Ratio of geometric means: 0.96 · 95% CI 0.93 to 1.00
  • Tolvaptan MR 50 mg vs Placebo · ANCOVA · p = 0.0298 · Ratio of geometric means: 0.96 · 95% CI 0.93 to 1.00
  • Tolvaptan IR 60/30 mg vs Placebo · ANCOVA · p = 0.2306 · Ratio of geometric means: 0.98 · 95% CI 0.94 to 1.01

Adverse events

Collected over Adverse events were collected from the time of signing the informed consent, throughout the 8 week treatment period and for 7 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan MR 50 mg0/45 (0%)3/45 (6.7%)27/45 (60%)
Tolvaptan MR 80 mg0/44 (0%)1/44 (2.3%)25/44 (56.8%)
Tolvaptan IR 60/30 mg0/44 (0%)1/44 (2.3%)32/44 (72.7%)
Placebo0/42 (0%)1/42 (2.4%)18/42 (42.9%)
Most frequent serious events
Most frequent serious events
EventTolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlacebo
Hepatic enzyme increasedInvestigations0/450/440/441/42
Alanine aminotransferase increasedInvestigations0/451/440/440/42
Liver function test abnormalInvestigations0/450/441/440/42
Sinus tachycardiaCardiac disorders1/450/440/440/42
Blood creatinine increasedInvestigations1/450/440/440/42
DehydrationMetabolism and nutrition disorders1/450/440/440/42
Renal painRenal and urinary disorders1/450/440/440/42
Most frequent other events
Showing 10 of 12
Most frequent other events
EventTolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlacebo
ThirstGeneral disorders15/4515/4419/446/42
NocturiaRenal and urinary disorders14/4514/4418/443/42
PolyuriaRenal and urinary disorders11/4511/4413/443/42
PollakuriaRenal and urinary disorders8/459/4412/443/42
Dry mouthGastrointestinal disorders7/457/442/441/42
HeadacheNervous system disorders1/451/447/441/42
PolydipsiaMetabolism and nutrition disorders7/456/445/442/42
FatigueGeneral disorders3/452/446/441/42
NauseaGastrointestinal disorders2/451/442/444/42
Renal painRenal and urinary disorders1/451/442/443/42

Baseline characteristics

All participants randomized to treatment.

Age, Continuous
Age, Continuous(years)Tolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlaceboTotal
Mean34.1 ± 10.135.8 ± 7.932.2 ± 7.633.9 ± 8.134.0 ± 8.5
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan MR 50 mgTolvaptan MR 80 mgTolvaptan IR 60/30 mgPlaceboTotal
Female1823202384
Male2722242093
08

Study locations

35 sites
  • Otsuka Investigational Site
    Huntsville, Alabama 35802, United States
  • Otsuka Investigational Site
    Mobile, Alabama 36617, United States
  • Otsuka Investigational Site
    Peoria, Arizona 85381, United States
  • Otsuka Investigational Site
    Tempe, Arizona 85284, United States
  • Otsuka Investigational Site
    Los Angeles, California 90025, United States
  • Otsuka Investigational Site
    San Diego, California 92108, United States
  • Otsuka Investigational Site 2
    Aurora, Colorado 80045, United States
  • Otsuka Investigational Site
    Aurora, Colorado 80045, United States
  • Otsuka Investigational Site
    Denver, Colorado 80210, United States
  • Otsuka Investigational Site
    New Haven, Connecticut 06510, United States
  • Otsuka Investigational Site
    Jacksonville, Florida 32216, United States
  • Otsuka Investigational Site
    Melbourne, Florida 32935, United States
  • Otsuka Investigational Site
    Atlanta, Georgia 30322, United States
  • Otsuka Investigational Site
    Augusta, Georgia 30901, United States
  • Otsuka Investigational Site
    Peoria, Illinois 61602, United States
  • Otsuka Investigational Site
    Mishawaka, Indiana 46545, United States
  • Otsuka Investigational Site
    Kansas City, Kansas 66160, United States
  • Otsuka Investigational Site
    Paducah, Kentucky 42003, United States
  • Otsuka Investigational Site
    Shreveport, Louisiana 71101, United States
  • Otsuka Investigational Site
    Baltimore, Maryland 21224, United States
  • Otsuka Investigational Site
    Rockville, Maryland 20850, United States
  • Otsuka Investigational Site
    Boston, Massachusetts 02111, United States
  • Otsuka Investigational Site
    Detroit, Michigan 48236, United States
  • Otsuka Investigational Site
    Rochester, Minnesota 55905, United States
  • Otsuka Investigational Site
    Voorhees, New Jersey 08043, United States
  • Otsuka Investigational Site
    Buffalo, New York 14215, United States
  • Otsuka Investigational Site
    Chapel Hill, North Carolina 27599, United States
  • Otsuka Investigational Site
    Cleveland, Ohio 44106, United States
  • Otsuka Investigational Site
    Bethlehem, Pennsylvania 18017, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Otsuka Investigational Site
    Anderson, South Carolina 29621, United States
  • Otsuka Investigational Site
    Nashville, Tennessee 37205, United States
  • Otsuka Investigational Site
    Arlington, Texas 76015, United States
  • Otsuka Investigational Site
    Mission, Texas 78572, United States
  • Otsuka Investigational Site
    Charlottesville, Virginia 22908, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2011, a primary completion of Jul 2013 and a completion of Jul 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 5 years 1 month after primary completion. A results delay was requested in Jun 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Oct 14, 2011
Start
Oct 2011
Primary completionActual
Jul 2013
CompletionActual
Jul 2013
Results delay requested
Jun 12, 2014
Results first posted
Aug 13, 2018
Last update
Sep 27, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 27, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01451827
Responsible party
Sponsor
First posted
Oct 14, 2011
Start date
Oct 2011
Primary completion
Jul 2013
Completion
Jul 2013
Results posted
Aug 13, 2018
Last update
Sep 27, 2018

Study contacts

Frank Czerwiec, M.D., Ph.D.
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion